Singularity Biotech Overview
- Year Founded
-
2023
- Status
-
Out of Business
- Employees
-
5
- Latest Deal Type
-
Out of Business
Singularity Biotech General Information
Description
Developer of universal therapeutics designed for genetic retinal diseases. The company offers retinal organoid production technology to create treatments for various ophthalmic conditions, enabling people to help preserve their vision by addressing the underlying genetic causes of retinal degeneration.
Contact Information
Website
www.singbiotech.comCorporate Office
- 305, 3rd Floor, 12 Opaesan-ro
- 3-gil, Seongbuk-gu, Hawolgok-dong, BT-TI Convergence Centre
- Seoul
- South Korea
Corporate Office
- 305, 3rd Floor, 12 Opaesan-ro
- 3-gil, Seongbuk-gu, Hawolgok-dong, BT-TI Convergence Centre
- Seoul
- South Korea
Singularity Biotech Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Out of Business | 03-Oct-2025 | Completed | Out of Business | |||
| 4. Early Stage VC | 01-Jul-2025 | Completed | Generating Revenue | |||
| 3. Accelerator/Incubator | 05-Aug-2024 | Completed | Generating Revenue | |||
| 2. Accelerator/Incubator | Completed | Generating Revenue | ||||
| 1. Seed Round | 30-Apr-2024 | Completed | Generating Revenue |
Singularity Biotech Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Singularity Biotech Patents
Singularity Biotech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025110673-A1 | Method for producing retinal progenitor cells from retinal organoid and use thereof | Inactive | 21-Nov-2023 | ||
| EP-4556013-A1 | Pharmaceutical composition for treatment of eye diseases comprising retinal organoid-derived exosomes | Pending | 15-Jul-2022 | ||
| EP-4556013-A4 | Pharmaceutical composition for treatment of eye diseases comprising retinal organoid-derived exosomes | Pending | 15-Jul-2022 | ||
| US-20260240912-A1 | Pharmaceutical composition for treatment of eye diseases comprising retinal organoid-derived exosomes | Pending | 15-Jul-2022 | ||
| WO-2024014792-A1 | Pharmaceutical composition for treatment of eye diseases comprising retinal organoid-derived exosomes | Inactive | 15-Jul-2022 | A61K9/0048 |
Singularity Biotech Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Singularity Biotech FAQs
-
When was Singularity Biotech founded?
Singularity Biotech was founded in 2023.
-
Where is Singularity Biotech headquartered?
Singularity Biotech is headquartered in Seoul, South Korea.
-
What is the size of Singularity Biotech?
Singularity Biotech has 5 total employees.
-
What industry is Singularity Biotech in?
Singularity Biotech’s primary industry is Drug Discovery.
-
Is Singularity Biotech a private or public company?
Singularity Biotech is a Private company.
-
What is Singularity Biotech’s current revenue?
The current revenue for Singularity Biotech is .
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
